MediGene prunes back to promote growth next year
This article was originally published in Scrip
Rose growers prune back the dead wood each year to ensure strong robust growth for the following season. MediGene, the German biotech, is clearly hoping the horticultural approach will help it get back on a sustainable growth trajectory. This week the company unveiled plans to cut its workforce from 107 to 55 employees and reduce its running costs by some €5 million a year. "These measures will support our efforts to strengthen our pipeline through strategic transactions," MediGene spokesperson Julia Hofmann told Scrip.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.